The U.S. Food and Drug Administration has authorized Philip Morris International to market Zyn nicotine pouches as a less harmful alternative to cigarettes, according to a report by CNBC published June 30, 2026. The ruling makes Zyn the first smokeless nicotine pouch product in the country to receive a so-called Modified Risk Tobacco Product (MRTP) authorization from the agency.
The non-obvious detail buried in the announcement: the FDA’s decision covers specific Zyn flavors and nicotine strengths individually, not the entire product line — meaning Philip Morris still cannot make reduced-risk claims for every Zyn variety it sells in the U.S. without separate authorization for each one.
What the FDA’s MRTP authorization actually allows
An MRTP designation does not mean the FDA has declared Zyn safe. The authorization permits Philip Morris to tell consumers that switching completely from cigarettes to Zyn pouches reduces their exposure to harmful chemicals found in cigarette smoke. The agency reviewed scientific data showing that, because Zyn pouches produce no smoke and are not burned, users avoid combustion byproducts — the primary driver of smoking-related cancers and cardiovascular disease.
The FDA stopped short of an “exposure modification” order, which would have required proof that population-level health outcomes actually improve. Instead, it granted the less demanding “risk modification” authorization, which relies on chemical exposure data rather than long-term disease studies. That distinction matters: it means regulators have not yet confirmed that widespread Zyn use will reduce smoking-related deaths at the population level.
Philip Morris’s U.S. push behind Swedish Match
Philip Morris acquired Swedish Match — Zyn’s original manufacturer — in 2022 for roughly $16 billion, a deal that gave the tobacco giant a dominant position in the fast-growing oral nicotine category. Zyn already held more than 60 percent of the U.S. nicotine pouch market before this ruling, according to industry tracking data cited by CNBC. The MRTP authorization now gives the brand a government-endorsed marketing edge over competing products like On! and Velo, neither of which carries the same FDA-sanctioned reduced-risk claim.
Sales of Zyn in the U.S. surged after the product became a cultural flashpoint in early 2024, driven partly by viral social media content. By mid-2026 the brand had become one of the fastest-growing nicotine products in the country, with convenience store scan data showing double-digit year-over-year volume growth.
Public health split: cessation tool or new addiction pipeline?
Tobacco harm-reduction advocates welcomed the decision, arguing that any product that moves cigarette smokers away from combustion is worth endorsing. The logic follows what the FDA calls a “continuum of risk” framework — the idea that not all nicotine products are equally dangerous, and that steering adult smokers toward lower-risk alternatives can save lives even if the alternatives are not risk-free.
Critics push back hard on that framing. Anti-tobacco groups have raised concerns that Zyn’s popularity among teenagers and young adults who never smoked cigarettes could create a new generation of nicotine-dependent users rather than divert existing smokers. The Campaign for Tobacco-Free Kids has repeatedly argued that MRTP authorizations send a permissive signal to young people who interpret “less harmful than cigarettes” as “safe.”
The FDA’s own authorization language tries to thread that needle, restricting the approved marketing claims to adult cigarette smokers and prohibiting Philip Morris from implying that Zyn is safe or appropriate for non-smokers. Whether that restriction holds in practice — given how fluidly product marketing travels through social media — remains an open question regulators have yet to fully answer.
Nicotine pouches carry their own documented risks
Even with the reduced-risk designation, Zyn is not without health concerns. Nicotine pouches deliver concentrated nicotine through the gum tissue, and regular use is associated with gum recession, elevated blood pressure, and nicotine dependence. The pouches also contain additives including flavorings, stabilizers, and pH adjusters whose long-term effects have not been studied across decades the way cigarette ingredients have.
Nicotine itself — separate from the tar and carbon monoxide in cigarettes — constricts blood vessels, can affect fetal development, and sustains addiction. The FDA’s authorization acknowledges these risks but concludes that, on balance, the absence of combustion makes Zyn meaningfully less harmful for current smokers who switch entirely rather than use both products simultaneously — a behavior called “dual use” that the agency considers a risk to the ruling’s intended benefit.
Regulatory and commercial consequences ahead
Philip Morris is expected to update Zyn packaging and point-of-sale materials to reflect the new FDA-authorized claims within the coming months. Competing nicotine pouch makers will face pressure to file their own MRTP applications, a process that takes years and costs tens of millions of dollars in scientific research — an advantage that effectively entrenches Zyn’s lead in the smokeless nicotine market.
Congress is also watching. Several lawmakers have already called for the FDA to raise the minimum purchase age for all FDA tobacco-regulated nicotine products or to cap nicotine concentrations in pouches, concerns that are likely to resurface in committee hearings now that a federal agency has formally endorsed a pouch product as a cigarette alternative. The agency’s next decision point will be whether to extend similar authorizations to other Zyn SKUs — and how quickly competitors can mount a credible scientific challenge to Zyn’s first-mover advantage.
